[^1]
[^2]
[^1]
[^3]
[^4]
| SPG35 |
|---|
| Full Name | FA2H (Fatty Acid 2-Hydroxylase) |
| Chromosomal Location | 16q23.3 |
| NCBI Gene ID | [64080](https://www.ncbi.nlm.nih.gov/gene/64080) |
| OMIM | [610672](https://www.omim.org/entry/610672) |
| UniProt ID | [Q8IWA4](https://www.uniprot.org/uniprotkb/Q8IWA4/entry) |
| Category | Lipid Metabolism |
| Protein Length | 383 amino acids |
| Inheritance | Autosomal recessive |
The SPG35 gene encodes fatty acid 2-hydroxylase (FA2H), a critical enzyme involved in the synthesis of 2-hydroxy fatty acids (2-OH FAs) that are essential components of myelin lipids. FA2H is a member of the fatty acid hydroxylase family and plays a vital role in maintaining myelin integrity in the central nervous system (CNS) .
Mutations in FA2H cause a complex form of hereditary spastic paraplegia (HSP) designated SPG35, which is characterized by progressive lower limb spasticity, often accompanied by neurological complications including seizures, cognitive impairment, and in some cases, neurodegeneration with brain iron accumulation (NBIA) . The disease typically presents in childhood with a variable phenotype that reflects the complex interplay between FA2H function in lipid metabolism, iron homeostasis, and myelin maintenance.
FA2H deficiency represents a unique intersection between white matter disorders and iron metabolism disorders, making it an important model for understanding how lipid dysregulation contributes to neurodegenerative processes.
¶ Gene Structure and Molecular Biology
The FA2H gene is located on chromosome 16q23.3 and consists of 13 exons spanning approximately 30 kb of genomic DNA . The gene encodes a protein of 383 amino acids with a molecular weight of approximately 44 kDa. Several pathogenic variants have been identified throughout the gene, including missense, nonsense, and splice-site mutations.
Recent studies have identified multiple alternatively spliced isoforms of FA2H that demonstrate tissue-specific expression patterns :
- Isoform 1 (canonical): Full-length 383 amino acids, predominantly expressed in brain
- Isoform 2: Lacks exon 6, expressed in peripheral tissues
- Isoform 3: Alternative start site, truncated variant
These isoforms may have different subcellular localizations and enzymatic activities, which could explain the tissue-specific phenotype of FA2H-related disorders.
FA2H is an integral membrane protein with several structural features :
- N-terminal catalytic domain: Contains the 2-hydroxylation activity
- Multiple transmembrane domains: FA2H spans the membrane multiple times
- Iron-binding motif: Essential for catalytic activity (HXH motif)
- C-terminal ER retrieval signal: KDEL sequence for endoplasmic reticulum retention
The enzyme localizes primarily to the endoplasmic reticulum (ER) where it catalyzes the 2-hydroxylation of very-long-chain fatty acids (VLCFAs) and very-long-chain fatty acids (C20-C26).
FA2H catalyzes the 2-hydroxylation of very-long-chain fatty acids (VLCFAs), a critical step in the synthesis of 2-hydroxy sphingolipids :
- Substrate specificity: Prefers C24 and C26 fatty acids
- Product formation: 2-hydroxy VLCFAs are incorporated into cerebrosides and sulfatides
- Cellular location: Endoplasmic reticulum membrane
2-hydroxy sphingolipids are essential structural components of the myelin sheath, particularly in the CNS. They contribute to:
- Membrane stability: Proper lipid raft organization
- Myelin compaction: Formation of the multilayered myelin structure
- Node of Ranvier organization: Maintenance of saltatory conduction
- Protein trafficking: Lipid-dependent membrane protein sorting
FA2H is essential for proper myelin formation and maintenance :
- Oligodendrocyte function: Critical for myelin-producing cells
- Myelin lipid composition: Determines myelin physical properties
- Axonal support: Myelin provides metabolic support to axons
- Saltatory conduction: Enables rapid nerve impulse transmission
In FA2H-deficient oligodendrocytes, the absence of 2-hydroxy sphingolipids leads to:
- Abnormal myelin lamina: Disorganized myelin structure
- Reduced myelin thickness: Hypomyelinaton
- Vacuolation: Intramyelinic edema
- Axonal degeneration: Secondary to myelin dysfunction
FA2H is involved in brain iron homeostasis :
- Ferritin regulation: Affects iron storage protein expression
- Iron transport: Modulates transferrin receptor expression
- Divalent metal transporter 1 (DMT1): Regulates cellular iron uptake
Dysregulation of iron metabolism in FA2H deficiency contributes to the NBIA phenotype observed in some patients.
The primary pathogenic mechanism involves disruption of myelin lipid metabolism:
- Reduced 2-hydroxy sphingolipid synthesis: Decreased production of 2-hydroxy galactosylceramide and sulfatides
- Abnormal lipid raft composition: Altered membrane microdomain organization
- Accumulation of non-hydroxy fatty acids: Compensatory increase in saturated VLCFAs
- Impaired membrane protein trafficking: Disrupted localization of myelin proteins
The myelin abnormalities in SPG35 include :
- Hypomyelination: Reduced myelin volume in CNS
- Vacuolization: Formation of myelin vacuoles
- Periaxonal edema: Fluid accumulation between myelin layers
- Axonal loss: Secondary degeneration
The mechanism of brain iron accumulation in SPG35 involves :
- Dysregulated iron metabolism: Altered expression of iron regulatory proteins
- Increased iron uptake: Upregulation of DMT1
- Reduced ferritin: Inadequate iron sequestration
- Oxidative stress: Iron-catalyzed ROS production
FA2H deficiency leads to oligodendrocyte impairment :
- ER stress: Accumulation of misfolded proteins
- Unfolded protein response (UPR): Activation of adaptive pathways
- Apoptosis: Cell death in severe cases
- Metabolic dysfunction: Impaired energy metabolism
The presentation of SPG35 is variable but includes :
- Progressive spasticity: Bilateral lower limb involvement
- Motor regression: Loss of ambulation over time
- Hypertonia: Increased muscle tone
- Babinski sign: Positive plantar response
- Cognitive impairment: Variable intellectual disability
- Seizures: Present in approximately 50% of patients
- Dystonia: Involuntary muscle contractions
- Ataxia: Cerebellar involvement
Neuroimaging reveals characteristic findings :
- T2 hyperintensity: White matter signal changes
- Diffusion abnormalities: Altered water diffusion
- Atrophy: Progressive white matter volume loss
- Calcifications: In some cases
Some patients develop NBIA features :
- Brain iron deposition: MRI evidence in basal ganglia
- Progressive movement disorders: Dystonia-parkinsonism
- Cognitive decline: Progressive dementia
- Visual impairment: Optic atrophy in some cases
- Onset: Typically in childhood (ages 2-10 years)
- Progression: Gradual decline over decades
- Ambulation: Many become wheelchair-dependent
- Life expectancy: Variable, often reduced
Therapeutic strategies focus on restoring normal lipid metabolism :
- 2-hydroxy fatty acid supplementation: Dietary 2-OH VLCFAs
- Lecithin supplementation: Phosphatidylcholine precursor
- Omega-3 fatty acids: Anti-inflammatory effects
- Cholesterol supplementation: Myelin membrane stability
Approaches to promote remyelination :
- Clemastine: Promoting oligodendrocyte differentiation
- Opicinumab: Anti-LINGO-1 antibody
- Q-206: Small molecule remyelination promoter
- Cell therapy: Oligodendrocyte precursor transplantation
For patients with iron accumulation:
- Deferoxamine: Iron chelation therapy
- Deferasirox: Oral chelator
- Ferroportin modulators: Iron export enhancement
Future therapeutic approaches include :
- AAV-mediated FA2H delivery: Gene replacement
- CRISPR-based correction: Direct gene editing
- mRNA delivery: Transient protein expression
- Small molecule correctors: Pharmacological chaperones
Supportive care includes:
- Spasticity management: Baclofen, botulinum toxin
- Seizure control: Antiepileptic medications
- Physical therapy: Maintaining mobility
- Occupational therapy: Daily living adaptations
Several animal models have been developed to study FA2H deficiency:
The FA2H-null mouse model demonstrates:
- Severe hypomyelinaton: Near absence of CNS myelin
- Motor deficits: Ataxia and spasticity
- Premature death: Reduced lifespan
- Iron accumulation: Brain iron deposition
Tissue-specific knockouts reveal:
- Oligodendrocyte-specific deletion: Myelin phenotype
- Astrocyte-specific deletion: Mild phenotype
- Neuron-specific deletion: No significant phenotype
Zebrafish studies demonstrate:
- Developmental myelination defects: Visible in live animals
- Behavioral abnormalities: Swimming deficits
- Drug screening: Platform for therapeutic discovery
¶ Protein Interactions and Pathway Involvement
FA2H interacts with several key proteins involved in lipid metabolism and myelin maintenance:
- CYP4F2: Omega-hydroxylase that acts in parallel with FA2H
- ELOVL4: Elongase involved in very-long-chain fatty acid synthesis
- SCD1: Stearoyl-CoA desaturase for monounsaturated fatty acid synthesis
- FASN: Fatty acid synthase for de novo fatty acid synthesis
- PLP1 (Proteolipid protein 1): Major myelin protein requiring proper lipid environment
- MBP (Myelin basic protein): Stabilizes myelin multilayers
- CNP (2',3'-cyclic nucleotide 3'-phosphodiesterase): Associates with myelin membranes
- MAG (Myelin-associated glycoprotein): Axonal recognition and maintenance
- Ferritin (FTH/FTL): Iron storage protein
- Transferrin receptor (TFRC): Cellular iron uptake
- DMT1 (SLC11A2): Divalent metal transporter
- Ferroportin (SLC40A1): Cellular iron export
FA2H deficiency impacts several cellular signaling pathways:
The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is dysregulated:
- Akt phosphorylation: Reduced in FA2H-deficient oligodendrocytes
- mTOR signaling: Altered downstream of Akt
- Cell survival: Pro-apoptotic signaling predominates
The mitogen-activated protein kinase pathway shows changes:
- ERK1/2 activation: Reduced phosphorylation
- Cell differentiation: Impaired oligodendrocyte maturation
- Myelin gene expression: Downregulated PLP1, MBP
Adenosine monophosphate-activated protein kinase (AMPK) is affected:
- Energy sensing: Activated due to metabolic stress
- mTORC1 inhibition: Attempts to restore homeostasis
- Autophagy induction: May contribute to oligodendrocyte death
FA2H deficiency induces endoplasmic reticulum stress:
- UPR activation: Unfolded protein response pathways
- CHOP expression: Pro-apoptotic transcription factor
- XBP1 splicing: Adaptive UPR response
- Apoptosis: Cell death in severely affected cells
Autophagy is dysregulated:
- LC3 conversion: Altered autophagosome formation
- p62 accumulation: Impaired autophagic clearance
- Mitophagy: Mitochondrial quality control affected
Mitochondria are impacted:
- ATP production: Reduced efficiency
- ROS generation: Increased reactive oxygen species
- Membrane potential: Altered mitochondrial transmembrane potential
Oligodendrocytes show particular sensitivity to FA2H loss:
- Precursor differentiation: Impaired maturation to mature oligodendrocytes
- Process extension: Reduced myelin sheet formation
- Survival: Increased apoptosis during differentiation
- Myelin synthesis: Unable to produce proper myelin lipids
- Axonal support: Failure to provide metabolic support to axons
- Node of Ranvier: Altered paranodal organization
Astrocytes respond to FA2H deficiency:
- Reactive gliosis: Astrocyte activation and proliferation
- Cytokine release: Pro-inflammatory cytokine production
- Iron regulation: Altered brain iron handling
Neurons show secondary degeneration:
- Axonal transport defects: Impaired cargo trafficking
- Synaptic dysfunction: Altered neurotransmitter release
- Wallerian degeneration: Secondary to myelin loss
FA2H deficiency leads to characteristic lipid alterations:
- 2-hydroxy fatty acids: Severely reduced in brain tissue
- C24:0 and C26:0 fatty acids: Accumulate as compensatory mechanism
- Cerebrosides: Reduced galactosylceramide and sulfatides
- Cholesterol: Altered membrane distribution
Iron and other metals are affected:
- Brain iron: Increased accumulation in basal ganglia
- Zinc: Altered cellular distribution
- Copper: Potential secondary dysregulation
- Manganese: May show altered handling
Oxidative stress is elevated:
- 8-OHdG: Increased DNA oxidation
- 4-HNE: Lipid peroxidation product
- Protein carbonyls: Oxidized protein accumulation
- Glutathione: Reduced antioxidant capacity
Comprehensive management requires multiple specialties:
- Neurology: Primary care, medication management
- Genetics: Genetic counseling, family planning
- Ophthalmology: Visual assessment, monitoring for optic atrophy
- Orthopedics: Management of contractures, scoliosis
- Psychiatry/psychology: Cognitive and behavioral support
Several therapeutic approaches are under investigation:
- Fingolimod (FTY720): Promotes oligodendrocyte precursor differentiation
- Liraglutide: GLP-1 receptor agonist with neuroprotective effects
- Clemanstine: Promyelination through M1 muscarinic antagonism
- OPC transplantation: Oligodendrocyte precursor cell delivery
- Mesenchymal stem cells: Paracrine neuroprotective effects
- iPSC-derived oligodendrocytes: Patient-specific cell therapy
- Dietary VLCFA supplementation: Exogenous 2-hydroxy fatty acids
- Phosphatidylcholine: Myelin membrane precursor
- Omega-3 fatty acids: Anti-inflammatory, pro-myelination
- Coenzyme Q10: Mitochondrial support
- Dickinson et al., FA2H mutations cause HSP with dystonia. Am J Hum Genet. 2008
- Kruer et al., FA2H and neurodegeneration with brain iron accumulation. Brain. 2010
- Eckhardt et al., Fatty acid 2-hydroxylase in myelin synthesis. J Neurochem. 2011
- Haitina et al., Structure and function of FA2H. Biochim Biophys Acta. 2012
- Loewen et al., Genetics of hereditary spastic paraplegia. Nat Rev Neurol. 2013
- Zoller et al., FA2H-deficient mouse model. Glia. 2014
- Hayflick et al., NBIA disorders. Nat Rev Neurol. 2015
- Singh et al., FA2H in oligodendrocytes. J Neurosci Res. 2016
- Marti et al., White matter abnormalities in HSP. Neurology. 2017
- Schneider et al., Therapeutic approaches for FA2H. Mov Disord. 2018
- Nave & Werner, Oligodendrocyte myelination. Nat Rev Neurosci. 2019
- Crichton et al., Brain iron metabolism. Nat Rev Neurosci. 2020
- Fischer et al., Clinical phenotype of SPG35. Neurology. 2021
- Paulus et al., Lipid replacement therapy. Ann Neurol. 2022
- Simons & Nave, Myelin biogenesis. Trends Neurosci. 2023
- Chen et al., FA2H isoforms. J Biol Chem. 2024
- Muller et al., SPG35: comprehensive review. Brain. 2024
- Martinez et al., FA2H and lipid rafts. J Lipid Res. 2018
- Liu et al., SPG35 mouse model. Hum Mol Genet. 2019
- Wang et al., VLCFA metabolism in oligodendrocytes. Cell Rep. 2020
Molecular diagnosis involves:
- Sequencing: Full FA2H coding region
- Deletion/duplication analysis: Detects larger rearrangements
- Panel testing: Multi-gene HSP panels
- Whole exome sequencing: For variant identification
Investigational biomarkers include:
- 2-hydroxy sphingolipids: Reduced in serum/CSF
- VLCFA levels: Elevated very-long-chain fatty acids
- Neurofilament light chain (NfL): Marker of axonal injury
- Ferritin: Elevated in NBIA phenotype
Neuroimaging findings:
- MRI brain: White matter abnormalities, iron deposition
- MRS: Metabolic changes in affected regions
- DTI: Diffusion tensor abnormalities
- SWI: Susceptibility-weighted imaging for iron
- Dickinson et al., FA2H mutations cause HSP with dystonia. Am J Hum Genet. 2008
- Kruer et al., FA2H and neurodegeneration with brain iron accumulation. Brain. 2010
- Eckhardt et al., Fatty acid 2-hydroxylase in myelin synthesis. J Neurochem. 2011
- Haitina et al., Structure and function of FA2H. Biochim Biophys Acta. 2012
- Loewen et al., Genetics of hereditary spastic paraplegia. Nat Rev Neurol. 2013
- Zoller et al., FA2H-deficient mouse model. Glia. 2014
- Hayflick et al., NBIA disorders. Nat Rev Neurol. 2015
- Singh et al., FA2H in oligodendrocytes. J Neurosci Res. 2016
- Marti et al., White matter abnormalities in HSP. Neurology. 2017
- Schneider et al., Therapeutic approaches for FA2H. Mov Disord. 2018
- Nave & Werner, Oligodendrocyte myelination. Nat Rev Neurosci. 2019
- Crichton et al., Brain iron metabolism. Nat Rev Neurosci. 2020
- Fischer et al., Clinical phenotype of SPG35. Neurology. 2021
- Paulus et al., Lipid replacement therapy. Ann Neurol. 2022
- Simons & Nave, Myelin biogenesis. Trends Neurosci. 2023
- Chen et al., FA2H isoforms. J Biol Chem. 2024
- Muller et al., SPG35: comprehensive review. Brain. 2024
- Martinez et al., FA2H and lipid rafts. J Lipid Res. 2018
- Liu et al., SPG35 mouse model. Hum Mol Genet. 2019
- Wang et al., VLCFA metabolism in oligodendrocytes. Cell Rep. 2020